| INTRODUCTION
Angiogenesis, the process of developing new vascular lumen from the pre-existing vessels, has been deeply implicated in the progression and development of many diseases. 1, 2 It has been well documented that angiogenesis is essential for malignant tumors advancing from the dormant stage to a highly metastatic phenotype. 3 Previously published articles have provided substantial evidence for the necessity of targeting tumor angiogenesis. 4, 5 During the last decade, anti-angiogenic drugs have been designed to chiefly target the VEGF/VEGFR-2 signaling axis. 4 However, this therapeutic strategy has been greatly challenged for its indiscriminate targeting of both healthy and tumoral VEGF/VEGFR-2 pathways. 6 Thus, it is urgent to develop new drugs or novel therapeutic strategy for overcoming the challenge.
Simvastatin, a member of the statin family, has been widely used to lower lipid levels and reduce cardiovascular risk. 7 Due to its high efficacy, the mechanisms underlying simvastatin-induced cardiovascular protection have increasingly attracted researchers' attention. It has been reported that simvastatin showed disparate effects on hypoxia and inflammation-induced angiogenesis. 8 In addition, low and high doses of simvastatin had biphasic effects on endothelial proliferation and migration. 9 Although tumor angiogenesis has some similarity with inflammatory angiogenesis, the effects of simvastatin on tumor angiogenesis and the associated underlying mechanisms remain poorly understood.
Recently, HIF-1a, a critical factor for mediating angiogenesis, has been reported to be deeply involved in simvastatin-induced antitumor activities. 10 However, less is known about whether simvastatin induces tumor anti-angiogenesis and how HIF-1a is affected by the upstream signaling. We previously reported that metformin, a drug that activates AMPK, suppressed breast tumor angiogenesis by targeting the HIF-a/VEGF signaling pathway. 11 Similar to metformin, simvastatin is capable of inhibiting tumor proliferation by activating AMPK. 12 Together with this evidence, we therefore propose AMPKmediated HIF-1a inhibition to be a meaningful mechanism by which simvastatin induces tumor anti-angiogenesis. Thus, the aim of this study is to investigate the definite effect of simvastatin on tumor angiogenesis, and to reveal the involvement of the AMPK-HIF-1a pathway. Scientific. Rabbit anti-CD31 antibody (ab28364) was purchased from
| MATERIALS AND METHODS

| Cells and reagents
Abcam. Alexa Fluor 488-and 546-conjugated antibodies were commercially provided by Life Technologies.
| Tumor cell-conditioned medium
Briefly, 11 tumor cells were initially cultured in 10% FBS DMEM supplemented with simvastatin, AICAR, compound C, siRNA control, siRNA-HIF-1a, or the combined pretreatment for 12 or 24 hours.
After washing with PBS washing three times, cells were cultured in SFM for 24 hours. Then the TCM was collected and centrifuged to remove cell debris. The number of live cells in each corresponding dish was finally counted to make a correction of TCM loading.
| Tube formation assay
To mimic in vivo angiogenesis, in vitro HUVEC-mediated tube formation assay was carried out. 11 First, we used 100 lL VEGF-reduced Matrigel (Basement Membrane Matrix; BD Bioscience) to precoat the whole bottom of a 96-well plate. The Matrigel was allowed to polymerize at 37°C for approximately 30 minutes, then 15 000
HUVECs were seeded and cultured in SFM or TCM at 37°C. Twelve hours later, the formed capillary-like network was recorded by using a microscope. The length of formed endothelial networks was measured by using the software of ImageJ 2X (NIH, Bethesda, MD, USA).
| Proliferation assay
Cellular viability of HUVECs was determined by using CCK-8 (Dojindo, Japan) following the manufacturer's instructions. At the end of culture, the absorbance at 450 nm of each well was measured using a microplate reader. Finally, the cellular viability relative to the SFM group was calculated to observe the proliferative ability of HUVECs treated with different interventions. 2 weeks, and tumor volumes were calculated every 2-3 days by using the formula 1/2 9 (length 9 width 2 ).
| Animal models
| Immunoblotting
Briefly, the protein concentration of each sample was determined by the BCA protein assay. To determine the protein levels of HIF-1a 
| Immunohistochemistry and immunofluorescence
To observe changes in the perfusion status of tumors, TRITC-Lectin (Vector Laboratories) was i.v. injected into the tail veins of mice 15 minutes before they were killed. 13 The wholly extracted tumor tissues were prepared for further immunofluorescent and IHC staining as previously described. 11, 13 For IHC staining, the paraffinembedded tumor tissues were cut into 3-4-lm sections; for immunofluorescence staining, tumor tissues fixed by 4% paraformaldehyde were cut into approximately 6-lm sections. Tissue sections were double-stained with CD31 (Abcam) and a-SMA (Boster Bio) antibodies to detect the change in vascular pericyte coverage, which indicates vascular maturity.
| Statistical analysis
All quantitative data are represented as mean AE SD. One-way ANOVA and Student's t-test were used to detect the significant difference between two or multiple groups. Statistical analysis was carried out by using GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). Significance is indicated by *P < .05, **P < .01, and ***P < .001; ns indicates that there was no statistically significant difference between groups.
| Ethics statement
All experimental procedures were approved by the Committee of Institutional Animal Care and Use of Xi'an Jiaotong University (Xi'an, China). Methods were carried out were in accordance with the approved guideline. 
| Simvastatin suppressed in vitro tumor
angiogenesis by a paracrine mechanism
In our previous study, 11 breast tumor cells promoted endothelial cell-mediated angiogenesis by secretion of pro-angiogenic factor. We next evaluated whether simvastatin has potential to restrain paracrine mechanism-related angiogenic promotion using a range of 
| Simvastatin reduced expression levels of HIF1a and its downstream pro-angiogenic factors
Hypoxia-inducible factor-1a is a well-documented factor that induces both physiological and pathological angiogenesis. 16, 17 We therefore investigated the effect of simvastatin on HIF-1a protein levels. As shown in Figure 
| Sprouting ability of vessels in vivo restrained by AICAR
As HIF-1a is critical for tumor angiogenesis, we then focused on the effects of AICAR on in vivo tumor angiogenesis and the sprouting ability of tumor vessels. As shown in Figure 4A ,B, 4T1 tumors from mice treated with AICAR showed a significantly lower microvessel This AICAR-induced inhibition of tumor angiogenesis was further validated by the fact that AICAR-treated tumor cells secreted less VEGF and FGF-2 to the medium than that of control ( Figure 5F ).
Moreover, we also observed that AICAR had no obvious effect on cellular morphology of HUVECs (data not shown). These results indicated that AMPK activation by AICAR could inhibit breast tumor angiogenesis through a paracrine-related mechanism. To further investigate whether compound C abrogates simvastatin-induced angiogenic inhibition, we next detected the expression levels of p-AMPK, AMPK, HIF-1a, VEGF, and FGF-2 in vitro.
F I G U R E 3 Simvastatin (SMV) reduced hypoxia-inducible factor-1a (HIF-1a) protein levels by activation of AMP kinase (AMPK)
As shown in Figure 6H , combined simvastatin and compound C 
| DISCUSSION
In the current report, we showed that simvastatin inhibited breast tumor angiogenesis facilitated by tumor cell-derived VEGF and FGF-2, two pro-angiogenic factors. Underlying these activities is the ability of simvastatin to reduce tumoral HIF-1a protein levels by activating the upstream AMPK (Figure 7 ).
Although a number of studies have been increasingly focused on the antitumor activities of statins, 12, 22, 23 their anti-angiogenic potential is largely unknown. In fact, statin is the drug that was primarily designed for treatment of metabolic disorders and cardiovascular diseases. 24 It has been reported that statins showed pro-angiogenic potentials in ischemic disorders, 25, 26 while having anti-angiogenic effects on inflammation. 27 This discrepancy in pathological angiogenesis might be closely associated with the biphasic effects of statins on HIF-1a. 26, 28 However, less is known about their effects on tumor angiogenesis. Recently, Li and colleagues reported the anti-angiogenesis activities of simvastatin in human colorectal cancers. 29 Consistently, our results further confirm the anti-angiogenic potential of simvastatin by using a murine orthotopic breast cancer model with a focus on its underlying mechanism. Quantitative data are indicated as mean AE SD. **P < .01; ***P < .001. ns, no statistically significant difference (P > .05)
For many years, the cholesterol lowering effects of statins were considered to have contributed to most of its beneficial activities. 30 In the last decade, both clinical and preclinical studies have revealed several cholesterol-lowering independent mechanisms underlying statins' cardiovascular protection. 31 Kureishi and colleagues reported that simvastatin promoted angiogenesis in ischemic tissues in normocholesterolemic animals. 32 It appears that, regardless of whether sta- pathways has also been observed in other statins, 33, 34 such as atorvastatin and lovastatin. 35 Hence, direct anti-tumor activities may be not specific to a particular statin.
The current anti-angiogenic therapies have been greatly challenged by their targeting of normal vasculature. 6 The VEGF inhibitors are associated with increased risks of various cardiovascular pathologies, such as hypertension, cardiovascular ischemia, and thromboembolism. 36 Unlike these VEGF inhibitors, simvastatin had no significant effect on increasing the risks of fatal and non-fatal cardiovascular pathologies. 37 Thus, the discrepancy between these drugs in terms of cardiovascular complications suggests that statins might be safer than direct VEGF inhibitors for clinical applications. Considering the results reported in this paper, statins, like simvastatin, could be one of the choices that should be considered for targeting tumor angiogenesis. proteins in supernatants of 4T1 cells by ELISA (n = 6). Quantitative data are indicated as mean AE SD. *P < .05; **P < .01; ***P < .001. Con, control; ns, no statistically significant difference (P > .05) AMP kinase has emerged as a target for treating metabolic syndromes, malignancies, and cardiovascular diseases. 21, 38, 39 Recently, simvastatin has been reported to induce tumor cell cycle arrest by AMPK activation. 12 Consistently, we found that simvastatin treatment resulted in an elevated protein level of phosphorylated AMPK in breast tumors, whereas total protein levels of AMPK were not changed. This evidence is further supported by previously published results that the AMPK activator, metformin (a widely prescribed biguanide for type 2 diabetes), showed potential antitumor activities through multiple mechanisms. [40] [41] [42] One of the frequently observed mechanisms activating AMPK is an increase in the expression of upstream LKB1. 43 Although LKB1 expression was not detected in this paper, we could not exclude the involvement of LKB1 in mediating the activation of AMPK by simvastatin.
Further research should be focused on assessing the requirement of LKB1. 44 In addition, HIF-1a facilitates tumor angiogenesis when the suppressor gene is lost. 45 When activated, AMPK is able to restrain the function of the mTOR complex, which regulates the protein synthesis of HIF-1a. 46 This mechanism helps to explain why statin-induced AMPK activation suppresses tumor angiogenesis involving HIF-1a. 47 As AMPK activation has multiple activities, 39, 48, 49 
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